Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 studySrđan Verstovšek, Haifa Kathrin Al‐Ali, David Lavie et al.|The Lancet|2023Cited by 181
Momelotinib long-term safety and survival in myelofibrosis: integrated analysis of phase 3 randomized controlled trialsSrđan Verstovšek, Claire Harrison, Ruben A. Mesa et al.|Blood Advances|2023Cited by 48